

EDUCATION

Doctor of Pharmacy

1993, Saint John's University, New York, New York

College of Pharmacy and Allied Health Sciences

Bachelor of Science in Pharmacy

1991, Union University

Albany College of Pharmacy Albany, New York

CERTIFICATE PROGRAMS

Executive Program in Pharmaceutical Management

Center for Pharmaceutical Management Studies

2011, Rutgers University, Newark, NJ

Certificate Program in Pharmacoeconomics

Cost Effectiveness Analysis for Medical Technologies and Pharmaceuticals

2000, Harvard School of Public Health, Boston, Massachusetts

PROFESSIONAL EXPERIENCE (INDUSTRY)

Madrigal Pharmaceuticals – Executive Global Medical Director, Medical Affairs

May 2022 – Present

Baudax Bio – Vice President of Medical Affairs

May 2021 – May 2022 (RIF due to inability to raise)

Calliditas Therapeutics – Executive Director and Head of US Medical Affairs

January 2020 – April 2021 (RIF due to data readout)

Allena Pharmaceuticals – Executive Director and Head of Medical Affairs (Failed Phase 3 trial)

March 2019-December 2019 (RIF due to data readout)

scPharmaceuticals – Senior Director of Medical Affairs

May 2017 – March 2019 (RIF due to FDA CRL)

Cempra Pharmaceuticals - Senior Director, Medical Affairs

March 2016 - May 2017 (RIF due to FDA CRL)

Vanda Pharmaceuticals - Director, Medical Affairs Strategy, MSLs and Global Health Outcomes

January 2014 – March 2016 Successful launch in US and Germany

Ikaria - Manager of Field Medical Affairs

June 2009 – January 2014

Reliant Pharmaceuticals/Glaxo Smith Kline Senior Regional Medical Scientist II

May 2006 – June 2009 (Reliant acquired by Glaxo)

PROFESSIONAL EXPERIENCE (CLINICAL)

Associate Director of Pharmacy, Clinical Pharmacology Consultant and Research Services
University Hospital, Syracuse, New York
May 1998 – May 2006

Director of Pharmacy Services
University Hospital, Syracuse, New York
October 1996 - April 1998

Senior Clinical Pharmacist in Critical Care
University Hospital, Syracuse, New York
June 1993 - October 1996

PROFESSIONAL EXPERIENCE (CONSULTING)

Founder – Pharmaceutical Care Consultants (d.b.a.)
November 1993- Present

ACADEMIC APPOINTMENTS

Research Assistant Professor, Department of Pharmacology, 2026-Present
Associate Professor of Medicine, Division of General Medicine, Section–Clinical Pharmacology 2003 – 2006
Assistant Professor of Medicine, Division of General Medicine, Section-Clinical Pharmacology, 1998 – 2003
Assistant Professor of Nursing, School of Nursing, 1999 – 2006
Upstate Medical University, Syracuse, New York

Adjunct Associate Professor of Pharmacy Practice, September 1993 - 2006
Union University, Albany College of Pharmacy, Albany, New York

Adjunct Assistant Professor, March 2001 - 2006
Department of Pharmacy Practice of the Nesbitt School of Pharmacy
Wilkes University, Wilkes Barre, Pennsylvania

Teaching Assistant, July 1991 - May 1993
St. John's University, College of Pharmacy and Allied Health Sciences, New York, New York

CERTIFICATION

Board Certified Pharmacotherapist, BCPS Number 296236, 12/96-12/2011

LICENSURE

Registered New York State Pharmacist, License Number 040905, 9/91-5/25
Status is currently 'retired'

PROFESSIONAL SOCIETIES

Elected Member, American College of Clinical Pharmacology

Elected Member, American Society of Clinical Pharmacology and Therapeutics

Elected Member, American College of Clinical Pharmacy

Member, American Society of Health-system Pharmacists

Member, New York State Council of Health-system Pharmacists

Member, Central New York Society of Health-system Pharmacists

Graduate Member, Kappa Psi Pharmaceutical Fraternity

CONSULTANT/ADVISORY BOARDS

Scientific Advisory Board - Accreditation Council for Medical Affairs (ACMA), 2017 - 2018

Consultant Pharmacist – Miscellaneous Medical Defense Law Firms in New York State

Consultant Pharmacist - Burnet Park Zoo, Syracuse, New York, 1997

Consultant - New York State Education Department, Office of Professional Discipline, Prosecutions Division 1995.

EDITORIAL APPOINTMENT

Reviewer – Journal of Clinical Pharmacology 2007-2010

Contributing Editor- The New York State Journal of Health System Pharmacists in the area of Critical Care Medicine, 1995-2007

Referee-Journal of Pharmacy Technology, 1998 - 2007

Reviewer- American Journal of Health-System Pharmacy, 1998- 2007

GRANTS/RESEARCH

FDA office of Orphan Product Development **NIH grant:** Phase 2 Study of Pulsed Inhaled Nitric Oxide vs Placebo for Pulmonary Arterial Hypertension. PI Brahm Goldstein, Doug Greene, Joseph Medicis, Larry Palmisano, Lisa Cooper 1.6 million dollars over four years –high ranking -unfunded

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Pharmacokinetic and Pharmacodynamic Study of Ularitide in Treatment of Subjects with Acute Decompensated Heart Failure - \$45,000.00 per patient

A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) With Adjusted-Dose Oral Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Subjects With Non-Valvular Atrial Fibrillation

CV185030: A Phase III, Active (Warfarin) Controlled, Randomized, Double-Blind, Parallel Arm Study to Evaluate Efficacy and Safety of Apixaban in Preventing Stroke and Systemic Embolism in Subjects with Nonvalvular Atrial Fibrillation IND 66106 \$6,000.00 per patient

ATHENA: A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in patiENts With Atrial Fibrillation/Atrial Flutter (AF/AFL)

TRITON TIMI-38: A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention

A Prospective, Multi-Center Study Of The Ability Of The PD2i Cardiac Analyzer To Predict Risk Of Ventricular Tachyarrhythmic Events Such As, Sudden Cardiac Death (SCD), Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT) in High Risk Patients

Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome (EARLY ACS) - \$3,000.00 per patient

A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial – IMPROVE IT) - \$6,000.00 per patient

A Randomized, Double-blind, Parallel-Group, Phase 3, Efficacy and Safety Study of AZD6140 Compared with Clopidogrel for Prevention of Vascular Events in Patients with Non-ST or ST Elevation Acute Coronary Syndromes (ACS) PLATO - \$7,500.00 per patient

Pharmacogenomic sample collection from subjects experiencing myositis or rhabdomyolysis related to statin therapy \$1500.00 per patient

Amgen - A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin alfa Treatment on Mortality and Morbidity in Heart Failure (RED-HF) Subjects with Symptomatic Left Ventricular Systolic Dysfunction and Anemia – \$24,000.00 per patient

Torcetrapib follow up Lipid Treatment Assessment Project 2 \$ 250.00 per patient

A phase 3 study of the rennin inhibitor (aliskiren/hctz) vs. valsartan/hctz vs. aliskiren/valsartan/hctz in primary hypertension \$ 8,000.00 per patient

2006 - TCWYRE – Comparison of drug eluting stents (tacrolimus versus myclofenetil) \$ 14,000.00

Amgen Inc. Pharmaceuticals – \$82,400.00 – Darpoetin alfa in the ICU for Prevention of Transfusions, 2005

SUNY Health Science Center- Grant Projects - Initiation of Guidelines for Sedation, Analgesia, and NMJB in Critical Care. 1996 \$15,000.00 in total

Astra Pharmaceuticals - Efficacy and Tolerability of Candesartan Cilexetil in hypertensive patients who have failed ACE Inhibitor Therapy. 1999, \$8,000.00 in total

The Merck Pharmaceutical Award - “Cost Effectiveness of Fomepizole versus Ethanol in the Management of Acute Ethylene Glycol Toxicity” 2003 \$1,000.00 in total

SMALL GRANTS/AWARDS

2006 American Association of Poison Control Centers Scientific Project of the Year Award on Cost Effectiveness of Fomepizole.

2006 and 1998 United University Professionals – Professional Development Grants

2005 NYSCHP Lederle Research Award

Research: “Prevalence and Cost Savings of Therapeutic Interchange Among U.S. Hospitals”

2005 NYSCHP Glaxo Research Award

Research: “National Surgical Infection Prevention Guideline: Practice Analysis and Identification of Areas for Improvement in a Tertiary Care Teaching Hospital”

2004 NYSCHP Glaxo Research Award

Research: “Antimicrobial True Vs. Pseudo Allergy” and Seymour & Elizabeth Katz Memorial Fund Award Relationship between Nursing, Pharmacy & Medicine and Improving Patient Care through Jointly Conceived and Implemented Services

2003 NYSCHP Lederle Research Award for “National Survey on Therapeutic Interchange in Teaching and Non-Teaching Hospitals”

STUDY DESIGN EXECUTIVE COMMITTEE

Primary Investigator - Vanda Pharmaceuticals, Inc. – Research protocol for the development of a clinical database of individuals with Smith-Magenis Syndrome (SMS) and Sleep disturbances(Pro00015678)

Ikaria Inc, A multi-center randomized placebo controlled placebo controlled double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin

Reliant Pharmaceuticals, A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety of Omacor® for the Prevention of Recurrent, Symptomatic Atrial Fibrillation

AMGEN BIOMARKER HF SUBSTUDY - Sub-study of RED-HF to obtain echocardiograms on a subset of study patients as well as biomarker PG (both PD and PK) samples for exploratory analyses

PATENTS, INVENTIONS AND COPYRIGHTS

Schnitman, Robert; **Medicis, Joseph**; Potenziano, Jim 2010 Apparatus and Method for Monitoring Nitric Oxide Delivery US20130118486 A1

Potenziano, James; Green Douglas S; **Medicis, Joseph**: 2013 Method of identifying and treating preterm infant is at risk of Bronchopulmonary Dysplasia US20170212133 A1

PUBLICATIONS

Kim, Y., **Medicis, J.**, Davis, M. *et al.* Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients. *Adv Ther* **41**, 4335–4355 (2024).

Qian, C., Fishman, J., Szabo, S.M., Kim, Y., **Medicis, J.**, Rochon, H., Sun, R. and Charlton, M., 2024. Real-World Clinical Outcomes Associated with Progression and Cirrhosis in Metabolic Dysfunction-Associated Steatohepatitis. <https://doi.org/10.21203/rs.3.rs-4534923/v1>

Kim, Y., Qian, C., Fishman, J., Szabo, S.M., Rochon, H., Sun, R., **Medicis, J.** and Charleton, M., 2024. 1054-P: Characterizing Clinical and Economic Outcomes among Patients with MASH and Type 2 Diabetes Mellitus Treated with Glucagon-Like Peptide 1 (GLP1)—A Cohort Study. *Diabetes*, 73(Supplement_1).

Fitch K, Lau J, Engel T, **Medicis JJ**, Mohr JF, Weintraub WS., The cost impact to Medicare of shifting treatment of worsening heart failure from inpatient to outpatient management settings. *ClinicoEconomics and Outcomes Research*. 2018; (10): 855-863.

Boyer TD, **Medicis JJ**, Potenziano J, Jamil K, A multi-center randomized placebo controlled placebo controlled double-blind study to confirm the reversal of hepatorenal syndrome type 1 with terlipressin (REVERSE TRIAL) *Journal of Clinical Trials* July 2012 (4): 39 – 49.

Clark JE, Lazzaro RJ, Miller DA, in collaboration with **Medicis JJ** et. al. ASHP statement on the roles and responsibilities of the pharmacy executive. American Society of Health-System Pharmacists. *Am J Health Syst Pharm*. 2009; 66(5):499-50

Lehmann DF, Page N, Kirchman K, Sedore A, Guharoy S, **Medicis J**, Ploutz R, Weinstock R, Duggan D. Every Error a Treasure: Improving Medication Use with a non-punitive Reporting System. *The Joint Commission Journal on Quality and Patient Safety*. 2007; 33(7): 401-407

Lehmann DF, Page N, **Medicis JJ**, Formulary Management as a tool to improve medication use and gain physician support. *American Journal of Health System Pharmacy* 2007; 64: 464-466.

Lehmann DF, **Medicis JJ**, Franklin P. Polymorphisms and the Pocketbook: The Cost-Effectiveness of Cytochrome P450 2C19 Genotyping in the Eradication of Helicobacter pylori infection associated with Duodenal Ulcer. *Journal of Clinical Pharmacology* 2003; 43:1316-1323.

Darko W, **Medicis JJ**, Smith A, Guharoy R, Lehmann DF. Mississippi mud no more: Cost Effectiveness of pharmacokinetic dosage adjustment for vancomycin to prevent nephrotoxicity. *Pharmacotherapy* 2003; 23 (5):643-650.

Schachtner JM, Guharoy R, Speizer R, **Medicis JJ**. National Survey of Therapeutic Interchange Policy, Procedures, Cost Savings in United States Hospitals. *American Journal of Health System Pharmacy* 2002: (59) 529-533.

Mascia M, Kotch M, **Medicis J.**, Pharmacoeconomic Impact of Guidelines for Analgesia, Sedation, and Neuromuscular Blockade in Critical Care. *Critical Care Medicine* 2000: 28 (7) 2300-2306.

Rolland WA, Guharoy R, Ramirez L, Blair D. **Medicis JJ**, Khan U., Respiratory Distress Secondary to Both Amphotericin B Dexycholate and Lipid Complex Formulation. *Vet Human Toxicol* 2000: 42 (4) 222-223

Marx WH, DeMaintenon NL, Mooney KF, Mascia ML, **Medicis JJ**, Franklin PD, Sivak E, Rotello L., Cost Reduction and Outcome Improvement in the Intensive Care Unit. *The Journal of Trauma*. 1999: 46 (4) 625-629.

Guharoy R, **Medicis J.**, Methamphetamine Overdose: Experience with Six Cases. *Veterinary and Human Toxicology*. 1999: 41 (1) 28-30.

Guharoy R, **Medicis JJ**, Lehmann DF., Fatal Adverse Event Secondary to High Osmolality Contrast Agent. *Vet Human Toxicology*. 1998: 40 (5); 285-287.

Lehmann DF, **Medicis JJ.**, A Pharmacoeconomic Model to Aid in the Allocation of Ambulatory Clinical Pharmacy Services. *Journal of Clinical Pharmacology*. 1998; 38; 783-791.

Medicis JJ., Stork CM., Howland MA., Hoffman RS., Goldfrank LR., What Target Pralidoxime Concentration? *Clinical Toxicology*. 1997; 35 (2); 229-230.

Medicis JJ., Stork CM., Howland MA., Hoffman RS., Goldfrank LR., Pharmacokinetics of a Continuous versus Short Infusion of Pralidoxime in Human Volunteers. *Journal of Toxicology and Clinical Toxicology*. 1996; Volume 34(3); 289-295.

Medicis JJ., Taking Some of the Confusion Out of the Process of Applying to Post Baccalaureate Pharm. D. Programs. *Mortar and Pestle* 1991; Volume 9(10); 2-3.

ABSTRACTS/POSTERS

Fishman J., Kim Y., **Medicis J.**, Davis M., Nunag D., Gish R. Risk of Incident Extrahepatic Cancers Among Medicare Patients with Nonalcoholic Steatohepatitis (NASH) *Hepatology* 2024 80 Supplement 1 (S798-S799)

Fishman J., Qian C., Kim Y., Sun R., **Medicis J.**, Rochon H., Szabo S.M., Charlton M. Cirrhosis Among People with Metabolic-Dysfunction Associated Steatohepatitis (MASH) is a Key Driver of Clinical and Economic Burden Independent of Metabolic Syndrome - an Observational Study. **Obesity Facts** 2024 **17** (460-461) Supplement 1

Fishman, J., Kim, Y., **Medicis, J.**, Davis, M., Nunag, D., & Gish, R. G. (2024). FRI-283 Costs associated with non-alcoholic steatohepatitis disease progression in Medicare patients. *Journal of Hepatology*, 80, S494.

Fishman, J., Kim, Y., **Medicis, J.**, Davis, M., Nunag, D., & Gish, R. G. (2024). FRI-214 Risk of non-alcoholic steatohepatitis disease progression to more severe liver disease in Medicare patients. *Journal of Hepatology*, 80, S469-S470.

Tasian GE, Wade B. Gaebler JA , Kausz AT, **Medicis JJ**, Wyatt CM, Prevalence of Kidney Stones in Patients with Enteric Disorders, *Journal of the American Society of Nephrology* 2019 **30** (835)

Bensimhon DR, Peacock WF, Weintraub WS, Myers R, Carter JA, Deering K, **Medicis JJ**, Mohr JF., scFurosemide Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure: The FreEDom-HF Study. *Journal of Cardiac Failure* 2018; 24(8):S58

Smith NJ, Velez FF, Mahlis EM, **Medicis JJ**, Messina JC, Beckerman, Gricar J, Mahmoud R., Economic Impact Associated with a Reduction in Surgical Eligibility among Adult Patients with Chronic Rhinosinusitis - A Population Cost Offset Model. *Journal of Allergy and Clinical Immunology*. 2018; 141(2): AB165

Velez FF, Mahlis EM, **Medicis JJ**, Messina JC, Mahmoud RA., Economic Impact Associated with a Reduction in Surgical Eligibility among Newly Diagnosed Patients with Chronic Rhinosinusitis - A Managed Care Cost Offset Model *J. Man. Care Pharm.* 2017; 23, (10a): S62.

Medicis JJ, Lodise TP, Scoble PJ, Sargent WQ, Schultek BR, Gelone SP., Financial burden associated with the use of guideline concordant therapy for the treatment of hospitalized patients with community acquired bacterial pneumonia. *J. Man. Care Pharm.* 2017; 23, (10a): S61.

Zeitzer J, Dressman MM, Licamele L, Xiao D, Olivadoti M, **Medicis JJ**, Baroldi P, Polymeropoulos MH, Longitudinal Measures of Sleep Diaries Can Be Used Clinically to Assess Tasimelteon Effectiveness in Non-24-Hour Sleep-Wake Disorder, *Sleep* 2015; (38): A208

Marraffa JM, Stork SM, **Medicis JJ**, Hodgeman MJ, Cantor R., Massive Amlodipine Overdose Successfully Treated using High Dose Vasopressin. *J Toxicol Clin Toxicol* 2006; 44: 732

Marraffa JM, Stork CM, **Medicis JJ**. Cost-effectiveness of fomepizole versus ethanol in the management of acute ethylene glycol exposure. *J Toxicol Clin Toxicol* 2005;43:691. Also presented at Ross Poster Session 11/30/2005.

Guharoy R, Darko W, **Medicis J**. Outcomes of Activated Protein C Utilization: Three Years Experience in a Tertiary Care Teaching Hospital. Accepted for Presentation at the 2005 Spring Practice and Research Forum of the American College of Clinical Pharmacy, April, 2005 *Pharmacotherapy* 2005;25:477.

Marraffa JM, Stork CM, Howland MA, McMartin KC, **Medicis JJ**: Pharmacokinetics of intravenous fomepizole versus oral fomepizole in Healthy Human Volunteers: Preliminary results. *J Tox Clin Tox* 2004; 42:747. Poster Presentation at the North American Congress of Clinical Toxicology in Seattle, Washington, Sept 9-14, 2004.

Lehmann DF, **Medicis JJ**, Guharoy R., Cost-Effectiveness of CYP2C19 Genotyping in PUD from H. Pylori. (Abstract) *Clinical Pharmacology and Therapeutics* 2000: 67 (2); 132.

Medicis J, Jones E, Sinnott C, Weinstock R, Guharoy R, Lehmann D., The application of a pharmacoeconomic model to determine cost-effectiveness of academic detailing clinical pharmacy services in improving angiotensin converting enzyme inhibitor utilization in type-2 diabetics with albuminuria. (Abstract) *Pharmacotherapy* 1999: 19 (10) 1226.

Lehmann DF, Connell R, **Medicis JJ**, Newman N, Shanahan P., Cost-effectiveness of Routine Screening for Statin Induced Hepatitis. *Clinical Pharmacology and Therapeutics* (Abstract). 1999: 65 (2) 182.

Guharoy R, **Medicis JJ**, Lehmann DF., Cost-effectiveness model to assess the value of a clinical pharmacist in achieving Cholesterol NCEP goals. *International Pharmaceutical Abstracts* 1999: 33; 552.

Medicis JJ, Davi D, Guharoy R, Mascia MF., Microprocessed EEG Monitoring in Critical Care. *International Pharmaceutical Abstracts*. 1998:35 (21); 2251.

Anderson MD, **Medicis JJ**, Kusiowski KM, Marble EL, Stalder BA., Development and Implementation of a Risk Stratified Pharmaceutical Care Plan at a University Hospital. *International Pharmaceutical Abstracts*. 1998: 35 (21); 2230.

Stalder BA, Fry WR, Kametz TW, **Medicis JJ**, Guharoy R., Case report: Antiepileptic induced Stevens-Johnson Syndrome in a two year old male. *International Pharmaceutical Abstracts*. 1998: 35 (21); 2270.

Kusiowski KM, Allen AL, **Medicis JJ**, Guharoy R., Use of a Pharmacoeconomic Database to Justify Two Additional Pharmacists in a University Hospital. *International Pharmaceutical Abstracts*. 1998: 35 (21); 2368.

Lehmann DF, **Medicis JJ**,. Cost Benefit Analysis of Clinical Pharmacology Services in the Management of Hypertension with Co-Morbidities. (Abstract) *Journal of Clinical Pharmacology*. 1997; 37: 868

Mascia MF., Koch M., **Medicis J**,. Pharmacoeconomic Impact of the Use of Rational Guidelines for Provision of Analgesia, Sedation., and Neuromuscular Blockade in Critical Care. *Research in Progress* 1997; 17-18.

Medicis JJ., McLaughlin MA., Development, Implementation, and Tracking of a Staff-Driven Patient Focused Pharmaceutical Care Plan at a University Hospital (Abstract). International Pharmaceutical Abstracts. 1995: Volume 32(21); 2276.

Medicis JJ., Mascia M., A Preliminary Outcome and Cost Study of Sedatives and Neuromuscular Blockers in Critical Care. (Abstract) Syllabus of the American Society of Critical Care Anesthesiologists 1995; 28.

Medicis JJ., Stork CM., Hoffman RS., Howland MA., Improved 2-PAM Dosing Regimen in Human Volunteers: A Pharmacokinetic Study. (Abstract) Veterinary and Human Toxicology. 1994: Volume 36(4); 377.

CHAPTERS/BOOK REVIEW/LETTERS

Schachtner JM, **Medicis J.,** Book review - Handbook of Basic Pharmacokinetics including Clinical Applications, 5th Edition by Ritschel and Kearns. American Journal of Health System Pharmacy. 1999: 56 (19) 1999

Medicis J., Book review - Practical Pharmacoeconomics: How to Design, Perform and Analyze Outcomes Research by Baskin. American Journal of Health System Pharmacy. 1999: 56 (6) 585-586.

Stork CM., **Medicis JJ.,** Indication for use of intravenous N-Acetylcystine in Patients Unable to Tolerate Oral Administration for APAP Poisoning (Letter). Clinical Drug Investigation. 1995: Volume 10(4); 247-248.

NEWSLETTERS/HANDBOOKS

Medicis J., Editor, University Hospital Formulary Handbook, Published by University Hospital, 97-98,98-99,99-00, 00-01, 01-02, 02-03, 03-04, 04-05.

Mascia M, Medicis J., Variety of Methods Can Cut ICU Costs, Anesthesiology News, March 1997

Mascia MF, Medicis J, Guidelines for Rational Use of Analgesics, Sedatives, and NMJBs in Intensive Care, 1996, 1997

Lehmann D., Au W., Medicis J., Emergency Drug Handbook, Published by University Hospital, 1996

Medicis JJ., Page T., Lauenstein K., Use of Nonprotein Colloids Over Albumin Encouraged. University Hospital Pharmacy News. 1995:5 (2).

Medicis JJ., Theophylline-Monitoring for Toxicity. University Hospital Pharmacy News. 1994: 10(5).

Medicis J., Adverse Drug Reactions. University Hospital Pharmacy News. 1994: 10 (2).

Medicis J., Basics of Therapeutic Drug Monitoring. University Hospital Pharmacy News. 1993: 9 (2).

INVITED PRESENTATIONS

9/18: Effect of a Single Subcutaneous Infusion of Furosemide Compared with Intravenous Bolus on Vital Signs in Patients with Heart Failure (Bensimhon D, Medicis J) – Heart Failure Society of America Annual Meeting, Nashville, Tennessee.

2/10 – Competitive Intelligence on intravenous Sildenafil to entire sales and marketing teams – National Business Conference, Gaylord – Dallas, Texas

12/09 – Executive presentation on Competitive Intelligence – Ikaria headquarters, Clinton, New Jersey

5/09 – Collaborative Drug Therapy Management and Code 405- New York State Council of Health System Pharmacists, Sagamore, Lake George, New York

5/08 – A comparison of patient recall on medication information with and without pharmacist discharge counseling – American College of Clinical Pharmacy Annual Meeting

8/06 – Drug Induced Arrhythmias – Albany College of Pharmacy CE, Albany, New York

5/06 - Outgoing Presidential Address: New York State Council of Health System Pharmacists. Sagamore, Lake George, New York

4/05 – Presidential Address – Balance - New York State Council of Health System Pharmacists Annual Meeting, Sagamore, Lake George, New York

5/04- Pharmacogenetics – Applications in Patient Care New York State Council of Health System Pharmacists Annual Meeting, Sagamore, Lake George, New York

5/03 – Lecture - Collaborative Drug Therapy Management - Bringing the Practice of Pharmacy into the 21st Century to Improve Patient Care. New York State Council of Health System Pharmacists Annual Meeting, Rye Town Hilton, NY

12/02 - Platform Presentation - Comparison of Standard Sedation Assessment to BIS in Patients Who are on Neuromuscular Blockers, Joseph J. Medicis, Alan Hui, Carlos Lopez, William Marx, and Edward Sivak Presented at the Midyear Meeting of the American Society of Health System Pharmacists, 2002, Atlanta, Georgia

12/02 - Platform Presentation – “Big Boy Beds” and Cost-Effectiveness: A Method to Optimize Erythropoietin Utilization, Joseph J. Medicis, Adrienne L. Smith, and Roy S. Guharoy, Presented at the Midyear Meeting of the American Society of Health System Pharmacists, 2002, Atlanta, Georgia

12/02 – Platform Presentation - Optimizing Pharmacotherapy: A Pharmacist-Initiated Renal Dosing Protocol, Alan Hui, Roy Guharoy, Joseph Medicis, and Adrienne Smith, Presented at the Midyear Meeting of the American Society of Health System Pharmacists, 2002, Atlanta, Georgia

12/02 - Platform Presentation - Review of Escalating Prescription Drug Expenditures in 2001 and Potential Cost Savings, Roy Guharoy, Joe Medicis, Jeanna Maraffa, Presented at the Midyear Meeting of the American Society of Health System Pharmacists, 2002, Atlanta, Georgia

12-01 - Platform Presentation - Survey on Restriction and Therapeutic Interchange of Low Molecular Heparin Agents Among U.S. Teaching Hospitals and Cost-Savings Potential, Roy Guharoy, Joe Medicis, Jeanna Maraffa, and Alan Hui, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2001, New Orleans, Louisiana

12/01 - Platform Presentation - Cost-Effectiveness of Legislation Expanding the Scope of Pharmacist Practice to include vaccination. Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2001, New Orleans, Louisiana

12/01 – Platform Presentation - National Survey on Therapeutic Interchange of Implementation in a Tertiary Care Teaching Institution, Roy Guharoy, Jill Schachtner, Joe Medicis, Ron Speizer, David Lehmann, and Se

Choi, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2001, New Orleans, Louisiana

12/01 - Platform Presentation - National Survey on Practice of Conversion of Oral Medications to Nasogastric/PEG/J Tube, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2001, New Orleans, Louisiana

12/01 – Platform Presentation - Administration and Implementation of a Pharmacy Managed Automatic Conversion System in a Tertiary Care Teaching Hospital, Roy Guharoy, Ron Speizer, A. Pikulski, Joe Medicis, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2001, New Orleans, Louisiana

12/01- Platform Presentation - National Survey on Institutional Preparedness for Soon-To-Be Marketed Recombinant Active Protein C, Roy Guharoy, D. Blair, J. Medicis, and R. Speizer, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2001, New Orleans, Louisiana

12/01 - Platform Presentation - Amiodarone-Warfarin Interaction: Lessons Learned from Our Events, R. Guharoy, S. Choi, A. Smith, J. Medicis, and R. Yandon, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2001, New Orleans, Louisiana

9/01 Platform Presentation - Mississippi Mud No- More: Cost Effectiveness of Vancomycin Monitoring, New York State Infectious Disease Pharmacist Conference, Syracuse New York

12/00 - Platform Presentation - Drug Utilization Evaluation of Tramadol, Vasiliki K. Pappas, Adrienne Smith, Joseph J. Medicis, and William Darko, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - Clostridium Difficile Associated Diarrhea: Prevalence and Treatment in a Tertiary Care Teaching Hospital, W. Darko, R. Guharoy, J. Medicis, A.L. Smith, and V.K. Pappas, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - Determination of Institution Specific Aminoglycoside and Vancomycin Volumes of Distribution at a University Hospital. Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Hot Topics Presentation - Automated Order Entry Warning System to Reduce Electrolytes Induced Arrhythmias in Patients Receiving Digoxin. Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - Implementation of an Inpatient Clinical Pharmacology Consult Service: Improving Care and Generating Revenue. Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - Expanded Role of Certified Pharmacy Technicians in a Critical Care Satellite, Bradford J. Saemon, Joe Medicis, Gregg Stanley, Jackie Fetterly, and Roy Guharoy, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - Low-Molecular-Weight Heparins in Renal Dysfunction: Prescription for Disaster or Opportunity for Quality Pharmaceutical Care? Adrienne L. Smith, Joseph J. Medicis, Jill M.

Schachtner, and Roy Guharoy, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - National Survey on Therapeutic Interchange of Serotonin Inhibitor Antiemetics in U.S. Hospitals, Roy Guharoy, Adrienne Smith, Jill Schachtner, Ron Speizer, Joe Medicis, and Se Choi, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - Drug-Utilization Evaluation of Fluconazole at a University Hospital, Jill M. Schachtner, Roy Guharoy, and Joseph J. Medicis, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 – Platform Presentation - Reducing Potential Acetaminophen Toxicity through a Novel Therapeutic Interchange, Joseph J. Medicis, A. L. Smith, and R. Guharoy, D. Lehmann, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

12/00 - Platform Presentation - Improving Accurate Documentation of Sampling Times with Drug Levels, Peter A. Rosher, J. J. Medicis, N. Page, and R. Guharoy, Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 2000, Las Vegas, Nevada.

10/00 - Lecture - ICU Pharmacology in the Y2K. - Critical Care Nursing Symposium - Syracuse, New York.

10/00 – Platform Presentation - Lehmann, DF, Medicis J., Cost-Effectiveness of CYP2C19 Genotyping in PUD from H. pylori. Annual Meeting of the American Society of Pharmacology and Clinical Therapeutics, 2000, Los Angeles, California.

3/00 - Platform Presentation - Pharmacy Day at the Capitol 2001 with Senator Kemp Hannon. Albany, New York.

12/99 - Platform presentation - Medicis JJ, Smith A, Guharoy., Four Year Experience with a Pharmaceutical Care Plan: Lessons Learned. American Society of Health System Pharmacists Midyear Clinical Meeting. Orlando, Florida.

12/99 - Poster Presentation - Stanley G, Medicis J, Bryant B, Guharoy R. Retrospective Analysis of Adverse Events Associated with Generic Propofol. Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 1999, Orlando, Florida.

12/99 -Poster Presentation - Guharoy R, Medicis J, Yandon R, DeGrazio J, Speizer R. Improving Staff Awareness: “What’s Going On?” Via Utilization of a Descriptive Monthly Quality Management Report. Presented at the Clinical Midyear meeting of the American Society of Health-System Pharmacists, 1999, Orlando, Florida.

12/99 -Poster Presentation - Guharoy R, Choi S, Medicis J, DeGrazio J, Sedore A. Preventing Medication Errors: Critical Role of Pharmacy Generated Medication Administration Records. Presented at the Clinical Midyear meeting of the American Society of Health-System Pharmacists, 1999, Orlando, Florida.

12/99 -Poster Presentation - Schachter J, Medicis J, Marble E, Guharoy R. Drug Utilization Evaluation of Glycoprotein IIb/IIIa Receptor Antagonists (Pharm.D. Resident Project). Presented at the Midyear Clinical Meeting of the American Society of Health System Pharmacists, 1999, Orlando, Florida.

12/99 -Poster Presentation - Seaberg D, Guharoy R, Medicis J. Vancomycin Utilization in a Tertiary Care Teaching Institution (Pharm.D. Resident Project). Presented at the Midyear Meeting of the American Society of Health System Pharmacists, 1999, Orlando, Florida.

10/99 -Poster Presentation - Medicis J, Jones E., Sinnott C, Weinstock R, Guharoy R, Lehmann DF., The Application of Pharmacoeconomic Model to Determine Cost-Effectiveness of Academic Detailing Clinical Pharmacy Services in Improving ACE Inhibitor Utilization in Type II Diabetics With Albuminuria. Presenter at the Annual Meeting of the American College of Clinical Pharmacy, 1999, Kansas City, Missouri

4/99 – Lecture- Sedation in the Intensive Care Unit, Thoracic Lecture Series. Cardiopulmonary Surgeon Morning Conference.

2/99 – Lecture - Beyond Pain, Entering the Sedation Zone in the ICU, Physician Continuing Education Program, Syracuse New York.

12/98 - Platform Presentation - Guharoy R., Medicis J., Lehmann D. An Economic Model to Assess Pharmacist Participation in Achieving NCEP II. Cholesterol Reduction Goal (ASHP COMPETITIVE EDGE RESEARCH PROJECT). Presented at the ASHP Midyear Clinical Meeting, Las Vegas, Nevada and Annual Meeting of the New York Society of Hospital Pharmacists, 1999, Rochester, NY.

12/98 - Poster presentation- Medicis JJ, Davi D, Guharoy R, Mascia MF., Microprocessed EEG Monitoring in Critical Care at American Society of Health Care System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada.

12/98 - Poster presentation- Anderson MD, Medicis JJ, Kusiowski KM, Marble EL, Stalder BA., Development and Implementation of a Risk Stratified Pharmaceutical Care Plan at a University Hospital. at American Society of Health Care System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada.

12/98 -Poster presentation- Stalder BA, Fry WR, Kametz TW, Medicis JJ, Guharoy R., Case report: Antiepileptic induced Stevens-Johnson Syndrome in a two year old male. at American Society of Health Care System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada.

12/98 -Poster presentation- Kusiowski KM, Allen AL, Medicis JJ, Guharoy R., Use of a Pharmacoeconomic Database to Justify Two Additional Pharmacists in a University Hospital. at American Society of Health Care System Pharmacists Midyear Clinical Meeting, Las Vegas, Nevada, Published in Pharmacy Practice News.

10/97- Platform presentation on “ The Pharmacoeconomic Impact of Rational Use Guidelines on the Provision for Analgesia, Sedation, and Neuromuscular Blockade in Critical Care” at the American Society of Anesthesiologists Meeting, San Francisco, California.

4/96- Lectured on "Analgesia, Sedation and Neuromuscular Blockade in the ICU" to Critical Care Nurses at University Hospital, Syracuse New York.

4/96- Lectured on “Drugs Helping Patients to Find their Rhythm.” to New York State Nurses Association with the American Heart Association Annual Meeting, Syracuse, New York.

3/96- Lectured on “Pharmacotherapy of Arrhythmia.” Pharmacy Noon Rounds. University Hospital. Syracuse, New York.

12/95- Poster presentation - Medicis J., McLaughlin MA., "Development and Tracking of a Staff-Driven Patient Focused Pharmaceutical Care Plan at a University Hospital." at American Society of Health Care System Pharmacists Mid-year Meeting, Las Vegas, Nevada.

10/95- Poster presentation - Medicis J., Mascia M., "A Preliminary Outcome and Cost Study of Sedatives and Neuromuscular Blockers in Critical Care." at American Society of Anesthesiologists Annual Meeting, Atlanta Georgia.

4/95-Lectured on "Update of Cardiovascular Pharmacotherapy" to New York State Nurses Association with the American Heart Association Annual Meeting, Syracuse, New York.

11/94-Lectured on "Sedation and Neuromuscular Blockade in the ICU" to Pharmacists at University Hospital, Syracuse New York.

12/94-Panel Member on "Documenting Clinical Activities" to Pharmacists of Central New York Society of Hospital Pharmacists, Liverpool, New York.

9/94-Lectured on "Emergency Pharmacotherapy" to Pharmacists of Health Services Association, Syracuse, New York.

6/94-Platform presentation (Rated Outstanding) - Bhandary A., Medicis JJ., Masand P., "Prescription Patterns of Newer Antidepressants in a Resident Managed Clinic." American Psychiatric Association National Convention, Philadelphia, Pennsylvania.

5/94-Lectured on "Geriatric Pharmacotherapy" to Nursing Staff at Plaza Health Center, Syracuse, New York.

11/93- Lectured on "Clinical, Ethical, & Administrative Issues in the Treatment of Acid Pepsin Disorders" at University Hospital, Syracuse, New York.

8/93- Lectured on "New Treatment Modalities for Alzheimer's Disease" at The Kirpatrick Day Center, Syracuse, New York.

10/92-Lectured on "Pharmacokinetic Dosing of Aminoglycosides and Vancomycin in Renal Failure" to Faculty at Long Island Jewish Medical Center, New Hyde Park, New York.

8/92- Lectured on "New Frontiers for Treatment of Neurocysticercosis" to Faculty at Nassau County Medical Center, East Meadow, New York.

6/92- Lectured on "The Use of Amrinone as a New Treatment Modality for Calcium Channel Blocker Overdose" at the New York City Poison Control Center, New York, New York.

6/92- Lectured on "Pharmacology of the Neuromuscular Junction Blocking Agents" to Emergency Medicine Residents at Bellevue Medical Center, New York, New York.

2/92- Lectured on "Beta Lactam Hypersensitivity Reactions" to Faculty at Nassau County Medical Center, East Meadow, New York.

OFFICES

Appointed **Chairman**, Public Policy, American College of Clinical Pharmacy, 2008 - 2010

Elected to State Wide Office of **President** – New York State Council of Health System Pharmacists, 2005-2006 (State chapter of ASHP)

Elected to **Board of Directors** New York State Council of Health System Pharmacists, 1999-2004

Elected to **Vice President of Governmental Affairs**, New York State Council of Health System Pharmacists 1999-2000, 2001-2002, 2002-2003

Elected to President, Central New York Society of Health System Pharmacists, 1998

Elected to Chapter Secretary, Kappa Psi Pharmaceutical Fraternity, 1990

COMMITTEES

▪ **Hospital Committees**

Chair, Clinical Pharmacy Performance Improvement Team, June 1998- 2006

Chair, Pharmacy and Therapeutics Committee, University Hospital October 1997 - October 1999

Member, Quality Council, University Hospital, 1996 - 1998

Member, Medical Staff Quality Improvement Committee, 1997-2000

Member, Institutional Review Board, University Hospital 1996-2000

Certified in Advanced Cardiac Life Support 1992 - Present

Team Leader, Order Communications Process Improvement Team, and University Hospital 1995- 1996

Appointed to Clinical Practice Review Council, University Hospital 1995- 1996

Appointed to Pharmacy and Therapeutics Committee, University Hospital 1993 - 2006

Appointed to Antibiotic Subcommittee, University Hospital 1993 - 1996

Patient Education Committee, University Hospital 1994-1996

Appointed to Curriculum Assessment Committee - St. John's University 1993

▪ **Regional Committees**

Regional Facilitator, American College of Clinical Pharmacy, NY, 1997-Present

▪ **State Committees**

NYS Council of Health System Pharmacists State Wide Committees

-Chairman, Nomination Committee, 2006

-Amgen Oncology Leadership Grant Committee, 2002

-Professional Affairs 1999 - 2008

-Committee on Resolutions 1999 – 2016

-Governmental Affairs 1999-present (chair 1999-2004)

- Delegate to the House 98-2005, 2007, 2008

-President of the House of Delegates - 2006

▪ National Committees

Chairman, Public Policy Committee, American College of Clinical Pharmacology 2008-present

American Society of Health System Pharmacists – State Governmental Affairs Committee 1999-2006

TEACHING ACTIVITIES

♦ Diadatic

Upstate Medical University - MDCN 2067, Fourth Year Medical Student Curriculum for Elective in Clinical Pharmacology & Therapeutics, Lecture rating very good to excellent. 2002-2006

Upstate Medical University - Introduction to Pharmacology, Second Year Medical Student Pharm Elective, 2001-2006

Upstate Medical University - Advanced Pharmacology, Neuro Pharmacology, Nurse Practitioner Course, 1998-2006.

Upstate Medical University - Pharmacokinetic Principles. Clinical Pharmacology Elective for Medical Students: Therapeutics. Yearly, February 2000 - 2006

Albany College of Pharmacy, Wilkes College of Pharmacy, - Doctor of Pharmacy Student Rotation in Critical Care, Preceptor, Monthly

Upstate Medical University - Pharmacology in the Critically Ill Patient. Medical and Surgical Intensive Care Rotation. Syracuse, New York, 1993-2006

Upstate Medical University - Pharmacokinetic Principles in Critical Care. Medical Fellowship Program in Critical Care. Yearly, 1991-1997.

Upstate Medical University - Nonsteroidal Anti-inflammatory Agents-How Do they Differ? Medical Residency Program in Orthopedics. Yearly, 1995-2000.

Albany College of Pharmacy - Clinical Applications of Pharmacokinetic Principles. Pharmacist Continuing Education Course. Given in Syracuse, Binghamton, and Utica, New York. Yearly, 1993-1995.

Albany College of Pharmacy - Hospital Pharmacy Practice, Yearly, 1994 -1996

Program Initiator and Director, Pharmacy Practice Residency, University Hospital, Syracuse, New York, July 1998 – June 2006

Residents Trained:

Karen Anderson, Pharm.D.
Jennie Ayers, Pharm.D.
Jill Schachtner, Pharm.D.
Danielle Seaberg, Pharm.D.
Vasiliki Pappas, Pharm.D.
William Darko, Pharm.D.
Kelly Killus Pharm.D
Johnathan Bradshaw, Pharm.D.
Dan Geisler, Pharm.D.

Residents Precepted:

Alan Hui, Pharm.D.
Jeanna Marraffa, Pharm.D.
Amber Davis, Pharm.D.
Bishoy Luka, Pharm.D.
Jamie Nelson, Pharm.D.
Seth Peterson, Pharm.D.
Lisa Charneski, Pharm.D.
Danielle Blais, Pharm.D.
Sarah Barth, Pharm.D.
Dominica Pacific, Pharm.D.
Anita Shankar, Pharm.D.

Fellow Precepted:

Jeanna Marraffa, Pharm.D., ABAT

◆ Resident Research Projects Supervised

- ◆ Cost Benefit of an Antithrombotic Management Program Compared to Standard Medical Care. A Decision Tree Model. Karen Anderson, Pharm.D.
- ◆ Drug Related Problems in a Medical Resident Run Clinic, Jennie Ayers, Pharm.D.
- ◆ Determination of Institution Specific Aminoglycoside and Vancomycin Volumes of Distribution in Intensive Care, Oncology, and General Medicine Population, Jill M. Schachtner, Pharm.D.
- ◆ Cost Effectiveness of monitoring vancomycin serum concentrations in preventing nephrotoxicity in a tertiary care hospital, William Darko, Pharm.D.
- ◆ Comparison of Nursing Assessment of Sedation to BIS analysis in the ICU, Alan Hui, Pharm.D., Vasiliki Pappas, Pharm.D.
- ◆ A Comparison of Patient Compliance with and without Pharmacist discharge consultation. Danielle Blais, Domina Pacific

◆ Self-development as a teacher

Residency Learning System Training, Baltimore, Maryland, 1998

AWARDS/HONORS

Madrigal Symphony Award 2024

Ikaria Intellectual Property Inventor Award - 2013

Ikaria Impact and Corporate Achievement awards – 2011, 2012, 2013

Fellowship, American College of Clinical Pharmacology, 2009

New York State Council of Health System Pharmacists Dedicated Service Award, 2007

Bristol Myers Squibb Pharmacy Leadership Award, 2006

Novartis Pharmaceuticals Leadership Award, 2006

Pharmacist of the Year, Central New York Society of Health-System Pharmacists, 2005

Best Clinical Medication Management Award - University Health Consortium, 2005

Fellowship, American Society of Health System Pharmacist, 2004

Clinical Team of the Year, Upstate Medical University 2002

Clinical Practitioner of the Year Award - New York State American College of Clinical Pharmacy Chapter, 1998

Inducted into Rho Chi Pharmaceutical Honor Society, 1992

Recipient of Smith Kline and Beecham Pharmaceuticals Award for Superior Achievement in Clinical Pharmacy, 1991

Recipient of Kappa Psi Pharmaceutical Fraternity Scholarship Award, 1991

Finalist - American Pharmaceutical Society Patient Counseling Competition, 1990

Deans List – 1987, 1988, 1989, 1990, 1991, 1992, 1993

MEDIA INTERVIEWS

Collaborative Drug Therapy Management, NYS Assembly News, 2004

Effects of Nonsteroidal Anti-inflammatory Agents in the Elderly, NBC affiliate Syracuse, 6/97

FDA Rulings on Prescription Drug Advertising, NBC affiliate Syracuse, 8/97

Pharmacists as Immunizers, ABC affiliate Syracuse, 1/00

NYS Assembly TV Interview, Role of the Pharmacist in the Year 2000, Cable Channel 13 Syracuse, 3/00

Pharmacists as Immunizers, CBS affiliate, Syracuse, 11/02